San Diego, California is the next site for the BIO IP Counsels Committee Conference. On March 25, 2013, biotech IP counsel will gather for an event dedicated to providing in-house IP counsel opportunities to learn cutting edge issues, network with their peers, and to enjoy another great location. Here is the session line-up and confirmed speakers with more speaker confirmations to come. Visit BIO’s IP Counsels Committee Conference page to register and learn more.
Pre-Conference Workshop: Effecting and Managing Change
The panel will discuss lobbying and public messaging about IP. This workshop will provide an overview and illustrative anecdotes on how to lobby Congress and the administration on certain issues and how to craft an effective public communications strategy (e.g. in the patent litigation context).
Workshop Faculty:
Scott Klug, Public Affairs Director, Foley & Lardner LLP
Carol Stratford, PhD, Counsel, KaloBios Pharmaceuticals, Inc.
Julie Chase, Chief Executive Officer, Chase Communications
Seeds of Exhaustion: Analysis of Bowman v. Monsanto & the Shifting Doctrine of Patent Exhaustion
Moderator: Andrew Serafini, PhD, Partner, Fenwick & West LLP
Panelists:
Kevin Marks, Vice President & General Counsel, Roche Molecular Diagnostics
Mark P. Walters, Partner, Frommer Lawrence & Haug LLP
Paul Wolfson, Partner, WilmerHale
Mark Chapman, Partner, Carpmaels & Ransford
Any Port in a Storm – Section 271(e)(1) and the Continuing Debate Over Boundaries of Safe Harbor Exception
Moderator: David Tellekson, Partner, Fenwick & West LLP
Panelists:
Mark Sandbaken, PhD, Executive Director of Intellectual Property, Seattle Genetics
Paul Fehlner, Global Head of Pharma Intellectual Property, Novartis Pharma AG
Jeff Rennecker, Senior Corporate Counsel, Pfizer Inc.
The Method Patent Rollercoaster
In the Akamai and McKesson cases, the Federal Circuit addressed divided infringement and found itself closely divided. The law on direct infringement remains up for grabs, and the court’s en banc opinion may not be the last word on indirect infringement. Method patents also present unique challenge under sections 101, 112, 271(e)(1), 271(f), and 271 (g). This session will discuss problems and solutions in light of the evolving law on method patents, offering perspectives from a trial lawyer, a patent prosecutor, and in-house patent counsel.
Moderator: Don Ware, Partner, Foley Hoag LLP
Patent Opinions Revisited: New Risks, New Rewards
The decisions in In re Seagate, Global Tech, and C.R. Bard have created new standards and procedures — with inherent risks and potential rewards — to justify reliance on freedom-to-operate opinions at trial. This panel will address best practices for obtaining and relying upon opinions of counsel from the perspectives of a trial lawyer, in-house patent counsel, and a jury consultant.
Moderator: Barbara Fiacco, Partner, Foley Hoag LLP
Panelist: Dan Gallipeau, PhD, President, Dispute Dynamics, Inc.
The AIA and APA: Oversight of Patents and the Agency That Grants Them
Moderator: Romy Celli, Partner, Alston & Bird LLP
Panelist: Nancy Linck, Of Counsel, Rothwell, Figg, Ernst & Manbeck
Case Law Updates
This panel will provide an update on recent patent cases including how the lower courts have dealt with guidance from the Supreme Curt and Federal Circuit. Particularly, the panel will focus on cases dealing with claim construction, inequitable conduct, obviousness, and patentability, and provide perspectives from in-house and outside counsel.
Moderator: Jitty Malik,PhD, Partner, Alston & Bird LLP
Panelists:
Phil Makrogiannis, Division Lead IP Counsel, Life Technologies Inc.
John W. Cox, PhD, Counsel, Alston & Bird LLP
